Date: 2014-06-26
Type of information: Development agreement
Compound: antibiotics targeting Neisseria gonorrhoeae and enteric species utilizing a novel mechanism of action
Company: Debiopharm (Switzerland) Nobelex Biotech (Canada)
Therapeutic area: Infectious diseases
Type agreement: development
Action mechanism:
Disease: Neisseria gonorrhoeae and enteric species infections
Details: * On June 26, 2014, Debiopharm, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, and Nobelex Biotech, a Canadian company focusing on the discovery and early development of novel antimicrobial drugs, announced their collaboration for two discovery programs to develop antibiotics targeting Neisseria gonorrhoeae and enteric species utilizing a novel mechanism of action. These programs, which issue from Affinium’s FabI discovery platform acquired by Debiopharm in February 2014, will lead to the development of narrow-spectrum innovative antibiotics. Nobelex, recently founded by Affinium’s former management, will contribute their expertise in microbiology, medicinal chemistry and infectious diseases as well as their knowledge of the platform and experience in the development of innovative antibiotics. Debiopharm will bring its expertise in advancing projects through preclinical and clinical development. “Through this collaboration Debiopharm strengthens its position in the development of targeted antibiotics. These are the first new discovery projects initiated from the Affinium’s technology platform since Debiopharm’s acquisition with its two clinical-stage molecules, Debio 1450 and Debio 1452. However we will continue to initiate additional development projects from this rich platform for new narrow spectrum anti-infectives, having the potential to preserve the microbiome and to prevent acquired resistance” commented Andrés McAllister, Chief Scientific Officer, Debiopharm International SA.
Financial terms:
Latest news:
